Posted by Michael Wonder on 16 Aug 2021
InxMed's IN10018 receives U.S. FDA fast track designation for the treatment of platinum-resistant ovarian cancer
16 August 2021 - InxMed announced today the U.S. FDA has granted fast track designation to IN10018 for the treatment of platinum-resistant ovarian cancer patients.
IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor under clinical development stage in United States, Australia, and China.
